Avanos Medical Inc. Stock News

Avanos Medical today announced it entered into a definitive agreement to acquire OrthogenRx for $160 million. OrthogenRx currently makes viscosupplementation therapies to treat knee osteoarthritis pain, as well as its commercial hyaluronic acid (HA) therapy products GenVisc 850 and TriVisc. Avanos will purchase the company for $130 million in cash at closing and an additional […] The post Avanos Medical to buy OrthogenRx for $160M appeared first on Drug Delivery Business .

Brokerages predict that Avanos Medical, Inc. (NYSE:AVNS) will announce earnings of $0.40 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Avanos Medicals earnings, with the lowest EPS estimate coming in at $0.39 and the highest estimate coming in at $0.41. Avanos Medical posted earnings per share of []

Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Invesco Ltd. increased its stake in Avanos Medical, Inc. (NYSE:AVNS) by 21.2% in the 2nd quarter, HoldingsChannel reports. The fund owned 335,053 shares of the companys stock after acquiring an additional 58,537 shares during the period. Invesco Ltd.s holdings in Avanos Medical were worth $12,186,000 at the end of the most recent quarter. A number []

Brokerages forecast that Avanos Medical, Inc. (NYSE:AVNS) will post sales of $190.65 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Avanos Medicals earnings, with the lowest sales estimate coming in at $190.60 million and the highest estimate coming in at $190.70 million. Avanos Medical reported sales of []

UBS Asset Management Americas Inc. boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 2.0% during the second quarter, Holdings Channel.com reports. The fund owned 47,952 shares of the companys stock after purchasing an additional 923 shares during the quarter. UBS Asset Management Americas Inc.s holdings in Avanos Medical were worth $1,744,000 at the end []

Avanos Medical's (AVNS) third-quarter 2021 results gains from strength in the Pain Management segment.

Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALPHARETTA, Ga., Oct. 26, 2021 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2021 on T

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock?

Avanos Medical, Inc. (AVNS) CEO Joe Woody on Q2 2021 Results - Earnings Call Transcript

Avanos Medical Inc (NYSE: AVNS) reported a second-quarter FY21 adjusted EPS of $0.21, missing the consensus of $0.23. The sales of $186.4 million increased 14% Y/Y, beating the analyst estimate of

Shares of Avanos Medical (NYSE:AVNS) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 61.54% year over year to $0.21, which missed the estimate of $